Product/Service


DIA's 8th Annual Canadian Meeting: Fostering Innovation And Access To Drugs

Source: DIA
The biopharmaceutical community is experiencing a paradigm shift in drug development. Important global changes are occurring with respect to regulatory oversight to clinical trial design and execution.
Details

Click Here To Download:
Event Brochure: DIA's 8th Annual Canadian Meeting: Fostering Innovation And Access To Drugs

Program Overview
The biopharmaceutical community is experiencing a paradigm shift in drug development. Important global changes are occurring with respect to regulatory oversight to clinical trial design and execution. Several factors influencing these changes include:

  • New scientific approaches
  • Biomarkers and individualized medicine
  • Healthcare reform and the interplay between safety, pharmacovigilance, and effectiveness research

In order to remain competitive, Canada will need to foster innovation in these areas and facilitate market access to medicines. World market dynamics have led to increased opportunities for both industry and regulators to share information while at the same time, introducing new challenges regarding privacy and/or confi dentiality. This year's program will highlight information on improving efficiency in the running of clinical trials, discuss ways of streamlining federal and provincial regulatory and formulary approvals, and provide advice on strategies to overcome obstacles.

Learning Objectives
At the conclusion of this meeting, participants should be able to:

  • Discuss some of the recent advances in drug development (eg, biomarkers and individualized medicine) and the implications of these changes to academia, industry, regulators, payers and healthcare practitioners
  • Identify new clinical trial designs and efficiencies in the process; what is the impact of the new domestic and international processes on the conduct of clinical trials?
  • Explain strategies for gaining and retaining reimbursement; how are Health Technology Assessments utilized
  • Differentiate between the Canadian versus international regulatory alignment
  • Recognize how clinical development pre and postapproval is impacted by regulatory and market access collaboration

Click Here To Download:
Event Brochure: DIA's 8th Annual Canadian Meeting: Fostering Innovation And Access To Drugs


Need More Information? Just Ask.
Click the button below to directly contact the supplier. Use it to:
  • Ask a question.
  • Request more detailed information or literature.
  • Discuss your current project/application.
  • Request a quote.
  • Locate a distributor in your area.
  • Schedule a demo.

DIA

More From DIA

Please wait... busy